EU/3/04/247

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in February 2011 on request of the sponsor.

On 21 December 2004, orphan designation (EU/3/04/247) was granted by the European Commission to Wainwright Associates Limited, United Kingdom, for 17-allylamino-17-demethoxygeldanamycin for the treatment of multiple myeloma.

The sponsorship was transferred to Bristol-Myers Squibb International Corporation, Belgium, in October 2008.

Key facts

Active substance
17-Allylamino-17-demethoxygeldanamycin
Disease / condition
Treatment of multiple myeloma
Date of decision
21/12/2004
Outcome
Withdrawn
Orphan decision number
EU/3/04/247

Sponsor's contact details

Bristol-Myers Squibb International Corporation
Parc de l ‘Alliance
Avenue de Finlande 8
B-1420 Braine-l’Alleud
Belgium
Telephone: +32 2 352 7242
Telefax: +32 2 352 7179

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating